

Notice of References Cited

Application/Control No.

09/671,995

Applicant(s)/Patent Under
Reexamination
CHARI, RAVI V. J.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 1 of 7

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Hortobagyi, G, 1997, Docetaxel in breast cancer and a rationale for combination therapy, Oncology, Vol. 11, No. 6, Suppl., pp. 11-15.
	V	Roy, DC, et al, 1996, Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin, Journal of the National Cancer Institute, Vol. 88, No. 16, pp. 1136-1145.
	W	Krek, CE, et al, 1995, Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells, Protein Engineering, Vol. 8, No. 5, pp. 481-489.
	X	Roguska, MA, et al, 1994, Humanization of murine monoclonal antibodies through variable domain resurfacing, Proceedings of the National Academy of Sciences USA, Vol. 91, No. 3, pp. 969-973.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

172
52 5/6/02

Notice of References Cited

Application/Control No.

09/671,995

Applicant(s)/Patent Under
Reexamination
CHARI, RAVI V. J.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 2 of 7

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Liu, C, et al, 1996, Cure of large human colon cancer xenografts by a C242-maystansinoid conjugate, Proceedings of the American Association for Cancer Research, Vol. 37, pp. 466-467, Abstract No. 3183.
	V	Aoe, K, et al, 1996, Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer cell line, Proceedings of the American Association for Cancer Research, Vol. 37, pp. 375, Abstract No. 2560.
	W	Lynch, TJ, et al, 1997, Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin, Journal of Clinical Oncology, Vol. 15, No. 2, pp. 723-734.
	X	Liu, C, et al, 1997, The development of antibody delivery systems to target cancer with highly potent maystansinoids, Exp. opin. Invest. Drugs, Vol. 6, No. 2, pp. 169-172.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

52
5/6/02

Notice of References Cited

Application/Control No.

09/671,995

Applicant(s)/Patent Under
Reexamination
CHARI, RAVI V. J.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 3 of 7

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-5,919,815-A	07-1999	Bradley, et al.	514/449
	B	US-5,395,924-A	03-1995	Blatter, et al.	530/396
	C	US-5,639,641-A; pp.1	06-1997	Pedersen, et al. (only first page due to length)	435/69.6
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
-	U	Nguyen, DM, et al, 2001, Synergistic tumoricidal effect of the paclitaxel and 17 allylamino geldanamycin (17AAG) combination in non-small cell lung cancer: in vitro and in vivo analysis, Proceedings of the Am. Assoc. for Cancer Research, Vol. 42, pp. 68-69
	V	Trail, PA, 1999, Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin, Clinical Cancer Research, Vol. 5, No. 11, pp. 3632-3638.
	W	Morikawa, t, et al, 1995, Pulmonary malignant fibrous histiocytoma treated with cisplatin plus etoposide followed by surgery, Nihon Kyobu Shikkan Gakkai Zasshi, Japanese Journal of Thoracic Diseases, Vol. 33, No. 9, pp. 993-998 (English abstract only).
-	X	Chari, RVJ, et al, 2000, Dose-response of the anti-tumor effect of huN901-DM1 against human small-cell lung cancer xenografts, Proceedings of the American Association for Cancer Research, Vol. 41, pp. 693.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
5/6/02

Notice of References Cited

Application/Control No.

09/671,995

Applicant(s)/Patent Under
Reexamination
CHARI, RAVI V. J.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 4 of 7

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Fornier, M, et al, 1999, Update on the management of advanced breast cancer, Oncology, Vol. 13, No. 5, pp. 647-658.
	V	Kaufman, O, et al, 1997, Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections, Human Pathology, Vol. 28, No. 12, pp. 1373-1378.
	W	Gu, WZ, et al, Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines, Anti-Cancer Research, Vol. 10, No. 10, pp. 895-901.
	X	Chan, D, et al, 1997, Synergistic effects of doxorubicin and modulators of multidrug resistance in small cell lung cancer (SCLC) cells naturally expressing MDR-1, MRP and LRP phenotypes, Proceedings Am. Assoc. for Cancer Res., Vol. 38, pp. 591-592.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
5/6/02

Notice of References Cited

Application/Control No.

09/671,995

Applicant(s)/Patent Under
Reexamination
CHARI, RAVI V. J.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 5 of 7

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Yeh, YA, et al, 1995, Growth inhibitory action of brefeldin A with taxol and tiazofurin in human breast carcinoma cells, Cancer Biochemistry Biophysics, Vol. 15, No. 1, pp. 11-17.
	V	Milas, L, et al, 1994, Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel, Cancer Research, Vol. 54, no. 13, pp. 3506-3510.
	W	Vogel, CL, et al, 1999, Monotherapy of metastatic breast cancer: a review of newer agents, Oncologist, Vol. 4, No. 1, pp. 17-33.
	X	Perez, EA, 1999, Paclitaxel plus nonanthracycline combinations in metastatic breast cancer, Seminars in Oncology, Vol. 26, No. 1, Suppl. 2, pp. 21-26.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
5/6/02

Notic of Ref renc s Cited

Application/Control No.

09/671,995

Applicant(s)/Patent Under
Reexamination
CHARI, RAVI V. J.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 6 of 7

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Gianni, L, et al, 1998, Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies, Recent Results in Cancer Research, Vol. 152, pp. 314-322.
	V	Burris, HA, III, 2000, Docetaxel (Taxotere) in HER-2-positive patients and in combination with Trastuzumab (Herceptin), Seminars in Oncology, Vol. 27, No. 2, Suppl. 3, pp. 19-23.
	W	Perez, EA, 1999, Current management of metastatic breast cancer, Seminars in Oncology, Vol. 26, no. 4, Suppl. 12, pp. 1-10.
	X	Hortobagyi, GN, 1999, Recent progress in clinical development of doxorubicin (Taxotere), Seminars in Oncology, Vol. 26, No. 3, Suppl. 9, pp. 32-36.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
5/6/02

Notice of References Cited

Application/Control No.

09/671,995

Applicant(s)/Patent Under
Reexamination
CHARI, RAVI V. J.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 7 of 7

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Norton, L, et al, 1999, Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+), Proc Annu Meet Am Soc Clin Oncol, Vol. 18, A483.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR
5/6/02